Doctor of Osteopathy Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Douglas Johnston

Allergy & Immunology Greenville, SC Doctor of Osteopathy

NPI 1124048079 CMS profile 5024

200 Patewood Dr Ste A140, Greenville, SC 29615

Open in the dashboard

General payments

$329,453

606 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$949,404 paid to institutions, not to them · program years 2019–2022

Through program year 2023, Douglas Johnston of Greenville, SC is reported in the CMS Open Payments database as having received $329,453 across 606 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $949,404 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $21 1
2022 General $448 21
2021 General $98,817 160
2020 General $76,845 165
2019 General $153,323 259

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Douglas Johnston
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Douglas Johnston were reported at $0. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Douglas Johnston Allergy & Immunology median Middle half National median
2019 $153,323 $594 $163–$1,512 $163
2020 $76,845 $426 $106–$1,233 $114
2021 $98,817 $638 $157–$1,708 $132
2022 $448 $790 $205–$1,961 $149
2023 $21 $852 $220–$2,147 $160
2024 $0 $865 $203–$2,267 $164
2025 $0 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Shire North American Group Inc $107,540 108 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $70,726 69 payments
  3. Pharming Healthcare, Inc. $47,728 49 payments
  4. CSL Behring $32,017 43 payments
  5. BioCryst Pharmaceuticals, Inc. $28,664 40 payments
  6. BioCryst US Sales Co., LLC $12,424 29 payments
  7. Aimmune Therapeutics, Inc. $11,888 3 payments
  8. AstraZeneca Pharmaceuticals LP $7,343 61 payments
  9. Pfizer Inc. $4,691 35 payments
  10. Genentech USA, Inc. $2,306 13 payments
  11. Other $4,128 156 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $139,573 51 payments
  2. Honoraria $75,128 34 payments
  3. Consulting Fee $69,225 26 payments
  4. Travel and Lodging $35,065 90 payments
  5. Food and Beverage $10,451 403 payments
  6. Education $12 2 payments
Products named General payments · program years 2019–2023
  1. CINRYZE $114,835 100 payments
  2. RUCONEST $54,444 54 payments
  3. TAKHZYRO Genetic Disease $43,730 57 payments
  4. Haegarda $31,993 42 payments
  5. Orladeyo $20,372 37 payments
  6. PALFORZIA $11,888 3 payments
  7. TAKHZYRO Immunology $9,324 4 payments
  8. EUCRISA $4,657 33 payments
  9. Xolair $2,306 13 payments
  10. FIRAZYR $1,125 1 payment
  11. Other $3,631 209 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

606 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record